Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Experimental & Molecular Medicine
  • View all journals
  • Search
  • My Account Login
  • Explore content
  • About the journal
  • Publish with us
  • Sign up for alerts
  • RSS feed
  1. nature
  2. experimental & molecular medicine
  3. articles
  4. article
Expression of NDRG2 is related to tumor progression and survival of gastric cancer patients through Fas-mediated cell death
Download PDF
Your article has downloaded

Similar articles being viewed by others

Slider with three articles shown per slide. Use the Previous and Next buttons to navigate the slides or the slide controller buttons at the end to navigate through each slide.

Inhibitor of growth 3 induces cell death by regulating cell proliferation, apoptosis and cell cycle arrest by blocking the PI3K/AKT pathway

01 June 2018

Song Zhao, Long Wang, … Xianzhi Meng

SIRT1 inhibits chemoresistance and cancer stemness of gastric cancer by initiating an AMPK/FOXO3 positive feedback loop

12 February 2020

Yifei An, Bo Wang, … Qing Yang

FGF18–FGFR2 signaling triggers the activation of c-Jun–YAP1 axis to promote carcinogenesis in a subgroup of gastric cancer patients and indicates translational potential

15 September 2020

Jinglin Zhang, Chi Chun Wong, … Wei Kang

ZC3H15 promotes gastric cancer progression by targeting the FBXW7/c-Myc pathway

21 January 2022

Jianbing Hou, Pan Huang, … Hongjuan Cui

Targeting the E3 ligase NEDD4 as a novel therapeutic strategy for IGF1 signal pathway-driven gastric cancer

11 February 2023

Ke Wang, Yanping Yu, … Rui Zhang

Absent in melanoma 2 suppresses gastric cancer cell proliferation and migration via inactivation of AKT signaling pathway

15 April 2021

Dong Wang, Junwei Zou, … Zhengwu Cheng

TGF-β-induced PLEK2 promotes metastasis and chemoresistance in oesophageal squamous cell carcinoma by regulating LCN2

02 October 2021

Feng Wang, Chaoqi Zhang, … Jie He

Asporin represses gastric cancer apoptosis via activating LEF1-mediated gene transcription independent of β-catenin

14 June 2021

Zheng Zhang, Li Min, … Shutian Zhang

RUNX3 enhances TRAIL-induced apoptosis by upregulating DR5 in colorectal cancer

28 January 2019

Bo Ram Kim, Seong Hye Park, … Dae-Hee Lee

Download PDF
  • Open Access
  • Published: 01 December 2007

Expression of NDRG2 is related to tumor progression and survival of gastric cancer patients through Fas-mediated cell death

  • Seung-Chul Choi1,
  • Suk Ran Yoon,
  • Yuk Pheel Park,
  • Eun Young Song,
  • Jae Wha Kim,
  • Woo Ho Kim,
  • Young Yang,
  • Jong-Seok Lim &
  • …
  • Hee Gu Lee 

Experimental & Molecular Medicine volume 39, pages 705–714 (2007)Cite this article

  • 608 Accesses

  • 63 Citations

  • Metrics details

Abstract

Although N-myc downstream regulated gene 2 (NDRG2) has been known to be a tumor suppressor gene, the function of this gene has not been elucidated. In the present study, we investigated the expression and function of NDRG2 in human gastric cancer. Among seven gastric cancer and two non-cancer cell lines, only two gastric cancer cell lines, SNU-16 and SNU-620, expressed NDRG2, which was detected in the cytoplasm. Interestingly, NDRG2 was highly expressed in normal gastric tissues, but gastric cancer patients were divided into NDRG2-positive and -negative groups. The survival rate of NDRG2-negative patients was lower than that of NDRG2-positive patients. We confirmed that the loss of NDRG2 expression was a significant and independent prognostic indicator in gastric carcinomas by multivariate analysis. To investigate the role of NDRG2 in gastric cancer cells, we generated a NDRG2-silenced gastric cancer cell line, which stably expresses NDRG2 siRNA. NDRG2-silenced SNU-620 cells exhibited slightly increased proliferation and cisplatin resistance. In addition, inhibition of NDRG2 decreased Fas expression and Fas-mediated cell death. Taken together, these data suggest that inactivation of NDRG2 may elicit resistance against anticancer drug and Fas-mediated cell death. Furthermore, case studies of gastric cancer patients indicate that NDRG2 expression may be involved in tumor progression and overall survival of the patients.

Author information

Authors and Affiliations

  1. Stem Cell Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, 305-608, Korea

    Seung-Chul Choi

Authors
  1. Seung-Chul Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Suk Ran Yoon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuk Pheel Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eun Young Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jae Wha Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Woo Ho Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Young Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jong-Seok Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hee Gu Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Choi, SC., Yoon, S., Park, Y. et al. Expression of NDRG2 is related to tumor progression and survival of gastric cancer patients through Fas-mediated cell death. Exp Mol Med 39, 705–714 (2007). https://doi.org/10.1038/emm.2007.77

Download citation

  • Published: 01 December 2007

  • Issue Date: 01 December 2007

  • DOI: https://doi.org/10.1038/emm.2007.77

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Keywords

  • antigens, CD95
  • cell survival
  • NDRG2 protein, human
  • RNA
  • small interfering
  • stomach neoplasms
  • tumor suppressor proteins

This article is cited by

  • NDRG2 gene expression pattern in ovarian cancer and its specific roles in inhibiting cancer cell proliferation and suppressing cancer cell apoptosis

    • Fenhong Kang
    • Yanlong Wang
    • Yongjun Zhang

    Journal of Ovarian Research (2020)

  • RETRACTED ARTICLE: Expression and prognostic value of the aldehyde dehydrogenase 1 (ALDH1) and N-myc downstream regulated gene 2 (NDRG2) as potential markers in human astrocytomas

    • Peyman Karimi Goudarzi
    • Farzad Mehrabi
    • Hesam Abdolhoseinpour

    Tumor Biology (2016)

  • Low expression of N-myc downstream-regulated gene 2 (NDRG2) correlates with poor prognosis in hepatoblastoma

    • Jan Gödeke
    • Elke Luxenburger
    • Roland Kappler

    Hepatology International (2016)

  • Clinical and pathological significance of N-Myc downstream-regulated gene 2 (NDRG2) in diverse human cancers

    • Wei Hu
    • Yang Yang
    • Jianyuan Gao

    Apoptosis (2016)

  • Combined aberrant expression of N-Myc downstream-regulated gene 2 and CD24 is associated with disease-free survival and overall survival in patients with hepatocellular carcinoma

    • Bing Li
    • Qing Shao
    • Guofeng Chen

    Diagnostic Pathology (2014)

Download PDF

Advertisement

Explore content

  • Research articles
  • Reviews & Analysis
  • News & Comment
  • Current issue
  • Collections
  • Sign up for alerts
  • RSS feed

About the journal

  • Special Feature
  • Journal Information
  • Open access publishing
  • About the Editors
  • About the Partner
  • Contact
  • For Advertisers
  • Press Releases

Publish with us

  • For Authors & Referees
  • Submit manuscript

Search

Advanced search

Quick links

  • Explore articles by subject
  • Find a job
  • Guide to authors
  • Editorial policies

Experimental & Molecular Medicine (Exp Mol Med) ISSN 2092-6413 (online) ISSN 1226-3613 (print)

nature.com sitemap

About Nature Portfolio

  • About us
  • Press releases
  • Press office
  • Contact us

Discover content

  • Journals A-Z
  • Articles by subject
  • Nano
  • Protocol Exchange
  • Nature Index

Publishing policies

  • Nature portfolio policies
  • Open access

Author & Researcher services

  • Reprints & permissions
  • Research data
  • Language editing
  • Scientific editing
  • Nature Masterclasses
  • Nature Research Academies
  • Research Solutions

Libraries & institutions

  • Librarian service & tools
  • Librarian portal
  • Open research
  • Recommend to library

Advertising & partnerships

  • Advertising
  • Partnerships & Services
  • Media kits
  • Branded content

Career development

  • Nature Careers
  • Nature Conferences
  • Nature events

Regional websites

  • Nature Africa
  • Nature China
  • Nature India
  • Nature Italy
  • Nature Japan
  • Nature Korea
  • Nature Middle East
  • Privacy Policy
  • Use of cookies
  • Legal notice
  • Accessibility statement
  • Terms & Conditions
  • California Privacy Statement
Springer Nature

© 2023 Springer Nature Limited